表紙
市場調査レポート

癌診断の世界市場予測 2020年:ELISA, ELFA, PCR (ポリメラーゼ連鎖反応) , NGS (次世代シークエンシング) , IHC (免疫組織化学)

Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

発行 MarketsandMarkets 商品コード 332701
出版日 ページ情報 英文 181 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。
Back to Top
癌診断の世界市場予測 2020年:ELISA, ELFA, PCR (ポリメラーゼ連鎖反応) , NGS (次世代シークエンシング) , IHC (免疫組織化学) Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020
出版日: 2015年06月10日 ページ情報: 英文 181 Pages
概要

世界の癌診断市場は技術、用途および地域に基づいて区分されます。技術はさらにプラットフォーム型と機器型に区分されます。2015年において、機器型区分は同市場で大きなシェアを構成しています。バイオマーカー、イメージング、生検、内視鏡といった多様な分野における技術進歩、癌症例数の増加、高齢者人口の急増、政府イニシアチブの認識、および政府資金の増加は、世界の癌診断市場の成長を促進する主な要因となっています。しかし、バイオマーカーの高額な資本投資と便益費用比率の低さ、および熟練専門家の不足は、同市場の成長を抑制しています。新興諸国における医療インフラの改善およびコンパニオン診断の需要拡大は、癌診断市場へ成長の機会を提供しています。

当レポートでは、世界の癌診断市場について調査し、市場概要、製品・用途・地域別の市場規模と予測、競合環境の分析、および主要企業のプロファイルなどを提供しています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 世界の癌診断市場
  • 癌診断市場の地域別スナップショット
  • 癌診断市場:技術別

第5章 市場概要

  • 主な調査結果
  • イントロダクション
  • 市場ダイナミクス

第6章 世界の癌診断市場:技術別

  • イントロダクション
  • プラットフォームに基づいた癌診断
    • ポリメラーゼ連鎖反応 (PCR)
    • in Situ ハイブリダイゼーション (ISH)
    • 免疫組織化学 (IHC)
    • 次世代シークエンシング (NGS)
    • マイクロアレイ
    • フローサイトメトリー
    • その他の技術
  • 機器に基づいた癌診断
    • 画像診断
    • バイオプシー (生検)

第7章 世界の癌診断市場:用途別

  • イントロダクション
    • 乳癌
    • 肺癌
    • 大腸癌
    • メラノーマ (黒色腫)
    • その他の癌

第8章 市場:エンドユーザー別

第9章 世界の癌診断市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア
  • その他の地域 (RoW)

第10章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合状況・動向

第11章 企業プロファイル

  • イントロダクション
  • Becton, Dickinson and Company
  • GE Healthcare (General Electric Company の子会社)
  • Abbott
  • Roche
  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • Siemens Healthcare
  • C.R. Bard, Inc.

第12章 付録

図表一覧

目次
Product Code: MD 3480

According to the CDC, cancer is the second leading cause of mortality, causing ~584,881 deaths worldwide in 2013. Early diagnosis is the key to prevent the rising number of cancer-related deaths. The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms such as next-generation sequencing, DNA microarrays, and polymerase chain reaction (PCR). Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have augmented the growth of the cancer diagnostics market.

The instrument-based cancer diagnostics segment accounted for the largest share of the global the cancer diagnostics market, by technology, while breast cancer accounted for the largest share of the cancer diagnostics applications market, in 2014.

North America accounted for the largest share of the global cancer diagnostics market, followed by Europe, Asia, and the Rest of the World (RoW). In the coming years, the cancer diagnostics market is expected to experience the highest growth rate in the Asian region, with emphasis on India and China. These countries are expected to serve as revenue pockets for companies operating in the cancer diagnostics market.

The global cancer diagnostics market witnesses high competitive intensity as there are several big and many small firms operating in different segments of the market. These companies adopt various strategies (agreements/partnerships/joint ventures/collaborations, new product launches, geographical expansions, and acquisitions) to increase their market shares and establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the cancer diagnostics market. The report analyzes cancer diagnostics by technology, application, and geography
  • Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the cancer diagnostics market
  • Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various cancer diagnostic technologies across regions
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the cancer diagnostics market
  • Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the cancer diagnostics market

Table of Contents

1. Introduction

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Scope
    • 1.3.1. Markets Covered
    • 1.3.2. Years Considered for the Study
  • 1.4. Currency
  • 1.5. Limitations
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1.1. Research Methodology Steps
  • 2.1.2. Secondary and Primary Research Methodology
    • 2.1.2.1. Secondary Research
    • 2.1.2.2. Key Data From Secondary Sources
    • 2.1.2.3. Primary Research
    • 2.1.2.4. Key Industry Insights
  • 2.1.5. Key Data From Primary Sources
  • 2.1.6. Key Insights From Primary Sources
  • 2.1.7. Market Size Estimation Methodology
  • 2.1.8. Market Forecast Methodology
  • 2.1.9. Market Data Validation and Triangulation
  • 2.1.10. Assumptions for the Study

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Current Scenario
  • 3.3. Future Outlook
  • 3.4. Conclusion

4. Premium Insights

  • 4.1. Global Cancer Diagnostics Market
  • 4.2. Regional Snapshot of the Cancer Diagnostics Market
  • 4.3. Cancer Diagnostics Market, By Technology (2015 vs. 2020)

5. Market Overview

  • 5.1. Key Findings
  • 5.2. Introduction
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
      • 5.3.1.1. Rising Prevalence of Cancer
      • 5.3.1.2. Technological Advancements
      • 5.3.1.3. Initiatives Undertaken By Governments and Global Health Organizations to Spread Awareness About Cancer
      • 5.3.1.4. Growth in the Number of Private Diagnostic Centers
      • 5.3.1.5. Public-Private Partnerships to Enhance the Infrastructure of Diagnostic Imaging Centers
      • 5.3.1.6. Fda Support for Biomarker Development
      • 5.3.1.7. Launch of New Flow Cytometry Reagents for Diagnostics and Drug Discovery
    • 5.3.2. Restraints
      • 5.3.2.1. High Capital Investments & Low Benefit-Cost Ratio for Biomarkers
      • 5.3.2.2. Shortage of Helium
      • 5.3.2.3. High Cost of Diagnostic Imaging Systems Affecting Their Rate of Adoption in Emerging Markets
      • 5.3.2.4. Risk of High Radiation Exposure Likely to Limit the Usage of CT Scanners
      • 5.3.2.5. Dearth of Skilled and Experienced Personnel
    • 5.3.3. Opportunities
      • 5.3.3.1. Personalized Medicine
      • 5.3.3.2. Development of Mass Cytometry and the Combination of Cell-And Bead-Based Flow Cytometry Technologies
      • 5.3.3.3. Companion Diagnostics
      • 5.3.3.4. Improving Healthcare Infrastructure in Emerging Markets
      • 5.3.3.5. Miniaturized and Technologically Advanced Devices
    • 5.3.4. Challenges
      • 5.3.4.1. Stringent Regulatory Guidelines
      • 5.3.4.2. Hospital Budget Cuts A Key Challenge to Market Players
      • 5.3.4.3. Increasing Adoption of Refurbished Diagnostic Imaging Systems

6. Global Cancer Diagnostics Market, By Technology

  • 6.1. Introduction
  • 6.2. Platform-Based Diagnostics
    • 6.2.1. Polymerase Chain Reaction (PCR)
    • 6.2.2. in Situ Hybridization (ISH)
    • 6.2.3. Immunohistochemistry (IHC)
    • 6.2.4. Next-Generation Sequencing (NGS)
    • 6.2.5. Microarrays
    • 6.2.6. Flow Cytometry
    • 6.2.7. Other Technologies
  • 6.3. Instrument-Based
    • 6.3.1. Diagnostic Imaging
      • 6.3.1.1. Magnetic Resonance Imaging (MRI)
      • 6.3.1.2. Computed Tomography (Ct)
      • 6.3.1.3. Positron Emission Tomography (PET)
        • 6.3.1.3.1. Standalone Positron Emission Tomography
        • 6.3.1.3.2. Hybrid Positron Emission Tomography
      • 6.3.1.4. Mammography
      • 6.3.1.5. Ultrasound
    • 6.3.2. Biopsies

7. Global Cancer Diagnostics Market, By Application

  • 7.1. Introduction
    • 7.1.1. Breast Cancer
    • 7.1.2. Lung Cancer
    • 7.1.3. Colorectal Cancer
    • 7.1.4. Melanoma
    • 7.1.5. Other Cancers

8. Market, By End User

9. Cancer Diagnostics Market, By Region

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. U.S.
      • 9.2.1.1. Government Initiatives
      • 9.2.1.2. Increase in Cancer Incidence
    • 9.2.2. Canada
      • 9.2.2.1. High Incidence of Cancer
      • 9.2.2.2. Government Funding
  • 9.3. Europe
    • 9.3.1. Funding for Cancer Diagnostics Research
    • 9.3.2. Eu-5. (U.K., Germany, France, Italy, Spain)
      • 9.3.2.1. Strong Government Support
      • 9.3.2.2. Research Collaborations
      • 9.3.2.3. Increase in Diagnostic Imaging Centers
      • 9.3.2.4. Rising Public and Private Investments
    • 9.3.3. Rest of Europe (RoE)
      • 9.3.3.1. Aging Population
      • 9.3.3.2. Conferences Boosting Awareness
      • 9.3.3.3. Government Investments in Russia
  • 9.4. Asia
    • 9.4.1.1. China
      • 9.4.1.1.1. Expansion of International Players
      • 9.4.1.1.2. Aging Population and Increasing Cancer Incidence
    • 9.4.1.2. Japan
      • 9.4.1.2.1. Aging Population and High Healthcare Expenditure in Japan
    • 9.4.1.3. India
      • 9.4.1.3.1. Increasing Focus of International Players on India
    • 9.4.1.4. Rest of Asia
      • 9.4.1.4.1. Presence of International Players Boosting Market Growth
  • 9.5. Rest of the World (RoW)
    • 9.5.1.1. Government Initiatives Boosting Demand for Cancer Diagnostics
    • 9.5.1.2. Aging Population, Presence of International Players
    • 9.5.1.3. Increase in Cancer Incidences and Rising Government Expenditure
    • 9.5.1.4. Government Initiatives to Improve Healthcare Infrastructure

10. Competitive Landscape

  • 10.1. Overview
  • 10.2. Market Share Analysis
  • 10.3. Competitive Situation and Trends
    • 10.3.1. Collaborations/Agreements/Partnerships/Alliances
    • 10.3.2. New Product Launches
    • 10.3.3. Acquisitions
    • 10.3.4. Expansion
    • 10.3.5. Others

11. Company Profiles

  • 11.1. Introduction
  • 11.3. Becton, Dickinson and Company
    • 11.3.1. Business Overview
    • 11.3.2. Product Portfolio
    • 11.3.3. Key Strategy
    • 11.3.4. Recent Developments
  • 11.4. GE Healthcare (A Subsidiary of General Electric Company)
    • 11.4.1. Business Overview
    • 11.4.2. Product Portfolio
    • 11.4.3. Key Strategy
    • 11.4.4. Recent Developments
  • 11.5. Abbott
    • 11.5.1. Business Overview
    • 11.5.2. Product Portfolio
    • 11.5.3. Key Strategy
    • 11.5.4. Recent Developments
  • 11.6. Roche
    • 11.6.1. Business Overview
    • 11.6.2. Product Portfolio
    • 11.6.3. Key Strategy
    • 11.6.4. Recent Developments
  • 11.7. Thermo Fisher Scientific, Inc.
    • 11.7.1. Business Overview
    • 11.7.2. Thermo Fisher Scientific, Inc.: Company Snapshot
    • 11.7.3. Product Portfolio
    • 11.7.4. Key Strategy
    • 11.7.5. Recent Developments
  • 11.8. Agilent Technologies, Inc.
    • 11.8.1. Business Overview
    • 11.8.2. Agilent Technologies, Inc.: Company Snapshot
    • 11.8.3. Product Portfolio
    • 11.8.4. Key Strategy
    • 11.8.5. Recent Developments
  • 11.9. Illumina, Inc.
    • 11.9.1. Business Overview
    • 11.9.2. Product Portfolio
    • 11.9.3. Key Strategy
    • 11.9.4. Recent Developments
  • 11.10. Siemens Healthcare
    • 11.10.1. Business Overview
    • 11.10.2. Product Portfolio
    • 11.10.3. Key Strategy
    • 11.10.4. Recent Developments
  • 11.11. C.R. Bard, Inc.
    • 11.11.1. Business Overview
    • 11.11.2. Product Portfolio
    • 11.11.3. Key Strategy
    • 11.11.4. Recent Developments

12. Appendix

  • 12.1. Discussion Guide
  • 12.2. Available Customizations
  • 12.3. Related Reports
  • 12.4. Introducing RT: Real-Time Market Intelligence

List of Tables

  • Table 1: Rising Prevalence of Cancer is Driving the Growth of the Cancer Diagnostics Market
  • Table 2: High Capital Investment Restraining the Growth of this Market
  • Table 3: Emerging Markets Present an Array of Opportunities for the Growth of this Market
  • Table 4: Stringent Regulatory Guidelines are A Major Challenge in the Cancer Diagnostics Market
  • Table 5: Global Cancer Diagnostics Market Size, By Technology, 2013-2020 ($Million)
  • Table 6: Global Market Size, By Technology, 2013-2020 ($Million)
  • Table 7: Market Size for Platform-Based Diagnostics, By Region, 2013-2020 ($Million)
  • Table 8: Global Market Size for PCR, By Region, 2013-2020 ($Million)
  • Table 9: Global Market Size for PCR, By Application, 2013-2020 ($Million)
  • Table 10: Cancer Diagnostics Market Size for in Situ Hybridization, By Region, 2013-2020 ($Million)
  • Table 11: Global Market Size for in Situ Hybridization, By Application, 2013-2020 ($Million)
  • Table 12: Market Size for Immunohistochemistry, By Region, 2013-2020 ($Million)
  • Table 13: Global Market Size for Immunohistochemistry, By Application, 2013-2020 ($Million)
  • Table 14: Market Size for NGS, By Region, 2013-2020 ($Million)
  • Table 15: Global Market Size for NGS, By Application, 2013-2020 ($Million)
  • Table 16: Market Size for Microarrays, By Region, 2013-2020 ($Million)
  • Table 17: Global Market Size for Microarrays, By Application, 2013-2020 ($Million)
  • Table 18: Market Size for Flow Cytometry, By Region, 2013-2020 ($Million)
  • Table 19: Global Market Size for Flow Cytometry, By Application, 2013-2020 ($Million)
  • Table 20: Market Size for Other Technologies, By Region, 2013-2020 ($Million)
  • Table 21: Global Market Size for Other Technologies, By Application, 2013-2020 ($Million)
  • Table 22: Global Market Size, By Technology, 2013-2020 ($Million)
  • Table 23: Cancer Diagnostics Market Size for Diagnostic Imaging, By Product, 2013-2020 ($Million)
  • Table 24: Market Size for Diagnostic Imaging, By Region, 2013-2020 ($Million)
  • Table 25: Global Market Size for Imaging, By Application, 2013-2020 ($Million)
  • Table 26: Cancer Diagnostics Market Size for MRI, By Region, 2013-2020 ($Million)
  • Table 27: Market Size for CT, By Region, 2013-2020 ($Million)
  • Table 28: Market Size for PET, By Product, 2013-2020 ($Million)
  • Table 29: Market Size for PET, By Region, 2013-2020 ($Million)
  • Table 30: Market Size for Standalone PET, By Region, 2013-2020 ($Million)
  • Table 31: Market Size for Hybrid PET, By Region, 2013-2020 ($Million)
  • Table 32: Market Size for Mammography, By Region, 2013-2020 ($Million)
  • Table 33: Market Size for Ultrasound, By Region, 2013-2020 ($Million)
  • Table 34: Cancer Diagnostics Market Size for Biopsy, By Region, 2013-2020 ($Million)
  • Table 35: Global Market Size for Biopsy, By Application, 2013-2020 ($Million)
  • Table 36: Global Market Size, By Application, 2013-2020 ($Million)
  • Table 37: Market Size for Breast Cancer, By Region, 2013-2020 ($Million)
  • Table 38: Market Size for Lung Cancer, By Region, 2013-2020 ($Million)
  • Table 39: Market Size for Colorectal Cancer, By Region, 2013-2020 ($Million)
  • Table 40: Market Size for Melanoma, By Region, 2013-2020 ($Million)
  • Table 41: Cancer Diagnostics Market Size for Other Cancers, By Region, 2013-2020 ($Million)
  • Table 42: North America Market, By Country, 2013-2020 ($Million)
  • Table 43: North America: Market, By Technology, 2013-2020 ($Million)
  • Table 44: North America: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 45: North America: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 46: North America: Market, By Application, 2013-2020 ($Million)
  • Table 47: U.S.: Market, By Technology, 2013-2020 ($Million)
  • Table 48: U.S.: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 49: U.S.: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 50: Canada: Market, By Technology, 2013-2020 ($Million)
  • Table 51: Canada: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 52: Canada: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 53: Europe: Market, By Region, 2013-2020 ($Million)
  • Table 54: Europe: Market, By Technology, 2013-2020 ($Million)
  • Table 55: Europe: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 56: Europe: Cancer Diagnostics Instrument Market, By Technology, 2013-2020 ($Million)
  • Table 57: Europe: Market, By Application, 2013-2020 ($Million)
  • Table 58: EU-5: Market, By Technology, 2013-2020 ($Million)
  • Table 59: EU-5: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 60: EU-5: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 61: RoE: Market, By Technology, 2013-2020 ($Million)
  • Table 62: RoE: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 63: RoE: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 64: Asia: Market, By Country, 2013-2020 ($Million)
  • Table 65: Asia: Market, By Technology, 2013-2020 ($Million)
  • Table 66: Asia: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 67: Asia: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 68: Asia: Market, By Application, 2013-2020 ($Million)
  • Table 69: China: Market, By Technology, 2013-2020 ($Million)
  • Table 70: China: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 71: China: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 72: Japan: Market, By Technology, 2013-2020 ($Million)
  • Table 73: Japan: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 74: Japan: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 75: India: Market, By Technology, 2013-2020 ($Million)
  • Table 76: India: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 77: India: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 78: RoA: Market, By Technology, 2013-2020 ($Million)
  • Table 79: RoA: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 80: RoA: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 81: RoW: Market, By Technology, 2013-2020 ($Million)
  • Table 82: RoW: Cancer Diagnostics Platform-Based Market, By Technology, 2013-2020 ($Million)
  • Table 83: RoW: Cancer Diagnostics Instrument-Based Market, By Technology, 2013-2020 ($Million)
  • Table 84: RoW: Market, By Application, 2013-2020 ($Million)
  • Table 85: Collaborations/Agreements/Partnerships/Alliances, 2012-2015
  • Table 86: New Product Launches, 2012-2015
  • Table 87: Acquisitions, 2012-2015
  • Table 88: Expansions, 2012-2015
  • Table 89: Other Strategies, 2012-2015

List of Figures

  • Figure 1: Cancer Diagnostics Market Segmentation
  • Figure 2: Global Cancer Diagnostics Market : Research Methodology Steps
  • Figure 3: Sampling Frame: Primary Research
  • Figure 4: Break Down of Primary Interviews: By Company Type, Designation, and Region
  • Figure 5: Market Size Estimation Methodology: Bottom-Up Approach
  • Figure 6: Market Size Estimation Methodology: Top-Down Approach
  • Figure 7: Market Forecast Methodology
  • Figure 8: Data Triangulation Methodology
  • Figure 9: Platform-Based Diagnostics to Witness Highest CAGR of 25.3% From 2015 to 2020
  • Figure 10: Global Platform-Based Cancer Diagnostics Market Share, By Technology, 2015-2020
  • Figure 11: Global Cancer Diagnostics Market, By Geography
  • Figure 12: Largest and Fastest-Growing Cancer Diagnostic Applications, 2015-2020
  • Figure 13: Cancer Diagnostics Market Likely to Grow at A CAGR of 12.9% in the Forecast Period
  • Figure 14: Market, By Region and Application: North America Will Dominate the Cancer Diagnostics Market in 2015
  • Figure 15: Asia to Witness the Highest Growth Rate During the Forecast Period
  • Figure 16: Instrument-Based Technology Will Command Largest Market Share
  • Figure 17: Market: Drivers, Restraints, Opportunities, & Challenges
  • Figure 18: NGS, A Ground-Breaking Technology in Cancer Diagnosis
  • Figure 19: Ultrasound Accounted for the Largest Share of the Cancer Diagnostics Market for Imaging
  • Figure 20: Market Growth Will Be Driven By Rising Incidence & Prevalence of Breast and Lung Cancers
  • Figure 21: Lung Cancer Application is Expected to Grow at the Highest CAGR in the Forecast Period
  • Figure 22: New Product Launches Was the Key Growth Strategy for Market Players
  • Figure 23: Global NGS Market (For Cancer Diagnostics) Share Analysis, By Key Player, 2014
  • Figure 24: Global Microarrays Market (For Cancer Diagnostics) Share Analysis, By Key Player, 2014
  • Figure 25: Global Flow Cytometry (For Cancer Diagnostics) Market Share Analysis, By Key Player, 2014
  • Figure 26: Global MRI Imaging Market Share Analysis, By Key Player, 2014
  • Figure 27: Global CT Imaging Market Share Analysis, By Key Player, 2014
  • Figure 28: Global PET Imaging Market Share Analysis, By Key Player, 2014
  • Figure 29: Global Ultrasound Imaging Market Share Analysis, By Key Player, 2014
  • Figure 30: Battle for Market Share: Collaborations/Agreements/Partnerships/ Alliances Were Key Strategies
  • Figure 31: Becton, Dickinson and Company: Company Snapshot
  • Figure 32: GE Healthcare: Company Snapshot
  • Figure 33: Abbott: Company Snapshot
  • Figure 34: Roche Diagnostics: Company Snapshot
  • Figure 35: Illumina, Inc.: Company Snapshot
  • Figure 36: Siemens: Company Snapshot
  • Figure 37: C.R. Bard, Inc.: Company Snapshot
Back to Top